ATXS News and Press, Astria Therapeutics Inc. From 11/13/23

-- New Phase 1a Results Confirm Potential for STAR-0215 to Prevent HAE Attacks with Dosing 2 or 4 Times Per Year -- -- ALPHA-STAR Trial of STAR-0215 Initial Proof-of-Concept Data in Patients Now Expected Q1 2024 -- -- STAR-0310, Potential Best-in-Class OX40 Program for the Treatme...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Astria Therapeutics Inc. (ATXS) is expected to report $-0.51 for Q3 2023

2023-11-10 10:37:05 ET Major earnings expected before the bell on Monday include: Auxly Cannabis Group ( OTCQB:CBWTF ) Capital Product Partners ( CPLP ) Sundial Growers ( SNDL ) Tower Semiconductor ( TSEM ) Tyson Foods ( TSN ) For further deta...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) in Anaheim, Ca...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Imm...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., C...

2023-10-19 09:32:26 ET More on Astria TherapeuticS Astria Therapeutics: Too Much Baggage, Too Strong A Competition Astria Therapeutics prices $64 million securities offering Seeking Alpha’s Quant Rating on Astria TherapeuticS For further details see: ...

2023-10-12 01:05:11 ET More on Astria TherapeuticS Astria Therapeutics: Too Much Baggage, Too Strong A Competition Astria signs licensing deal with Ichnos Sciences to develop atopic dermatitis treatment Astria wins FDA fast track tag for lead candidate Seekin...

Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, tod...